PolyPid develops drug candidates that release medicine slowly at the treatment site, led by D-PLEX100 for preventing surgical site infections. PYPD reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Oppenheimer | Initiated | Buy | |
| Jul 21 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How PYPD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in PYPD in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PYPD is in one of them and how their past PYPD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PYPD in an article yet. Here's the latest on the wider market.
About PolyPid
PolyPid is a biopharmaceutical company based in Petach Tikva, Israel. It develops medicines that release drugs slowly and locally at the site of treatment. Its lead product candidate, D-PLEX100, combines its PLEX technology with the antibiotic doxycycline and is placed directly into the surgical site during surgery to help prevent surgical site infections. The company is also developing treatments for metabolic diseases and cancer, and it plans to license its PLEX technology to other drug developers. Its intended users are surgical patients and the hospitals that treat them.
- Headquarters
- Petach Tikva, Israel